The path to clinical proteomics research: Integration of proteomics, genomics, clinical laboratory and regulatory science

Korean Journal of Laboratory Medicine

Volumn 31, Issue 2, 2011, Pages 61-71

  Boja, Emily S ^a   Rodriguez, Henry ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biomarker; Immunoassays; MRM MS; Multiplex protein assays; Quantitative proteomics

Indexed keywords

BIOLOGICAL MARKER;

DIAGNOSIS, MEASUREMENT AND ANALYSIS; FOOD AND DRUG ADMINISTRATION; GENETICS; GENOMICS; HUMAN; MASS SPECTROMETRY; METHODOLOGY; NEOPLASM; PROTEOMICS; QUALITY CONTROL; REVIEW; STANDARD; UNITED STATES;

BIOLOGICAL MARKERS; CLINICAL LABORATORY TECHNIQUES; GENOMICS; HUMANS; MASS SPECTROMETRY; NEOPLASMS; PROTEOMICS; QUALITY CONTROL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79955432121     PISSN: 15986535     EISSN: None     Source Type: Journal    
DOI: 10.3343/kjlm.2011.31.2.61     Document Type: Review

References (71)

1. Etzioni R, Urban N, Ramsey S, Mcintosh M, Schwartz S, Reid B, et al. The case for early detection. Nat Rev Cancer 2003;3:243-52.
2. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 2005;563:23-60.
3. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24:971-83. (Pubitemid 44215392)
4. Garcia-Foncillas J, Bandrés E, Zarate R, Remirez N. Proteomic analysis in cancer research: potential application in clinical use. Clin Transi Oncol 2006;8:250-61.
5. Bouchal P, Roumeliotis T, Hrstka R, Nenutil R, Vojtesek B, Garbis SD. Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatographytandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis. J Proteome Res 2009;8:362-73.
6. Wiener MC, Sachs JR, Deyanova EG, Yates NA. Differential mass spectrometry: a label-free LC-MS method for finding significant differences in complex peptide and protein mixtures. Anal Chem 2004;76:6085-96.
7. Geiger T, Cox J, Ostasiewicz P, Wisniewski JR, Mann M. Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat Methods 2010;7:383-5.
8. Anderson L and Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5:573-88.
9. Wang H, Wong CH, Chin A, Kennedy J, Zhang Q, Hanash S. Quantitative serum proteomics using dual stable isotope coding and nano LC-MS/MSMS. J Proteome Res 2009;8:5412-22.
10. Lee J, Soper SA, Murray KK. Microfluidic chips for mass spectrometry-based proteomics. J Mass Spectrom 2009;44:579-93.
11. Pierobon M, Calvert V, Belluco C, Garaci E, Deng J, Lise M, et al. Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker. Clin Colorectal Cancer 2009;8:110-7.
12. Ramachandran N, Raphael JV, Hainsworth E, Demirkan G, Fuentes MG, Rolfs A, at al. Next-generation high-density self-assembling functional protein arrays. Nat Methods 2008;5:535-8. (Pubitemid 351761761)
13. Beirne P, Pantelidis P, Charles P, Wells AU, Abraham DJ, Denton CP, at al. Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis. Eur Respir J 2009;34:1376-82.
14. Kelleher MT, Fruhwirth G, Patel G, Ofo E, Festy F, Barber PR, et al. The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients. Target Oncol 2009;4:235-52.
15. Wang P, Whiteaker JR, Paulovich AG. The evolving role of mass spectrometry in cancer biomarker discovery. Cancer Biol Ther 2009;8:1083-94.
16. Whiteaker JR, Zhang H, Eng JK, Fang R, Piening BD, Feng LC, et al. Head-to-head comparison of serum fractionation techniques. J Proteome Res 2007;6:828-36.
17. Ernoult E, Bourreau A, Gamelin E, Guette C. A proteomic approach for plasma biomarker discovery with iTRAQ labeling and OFFGEL fractionation. J Biomed Biotechnol 2010;2010:927917.
18. Nirmalan NJ, Hughes C, Peng J, McKenna T, Langridge J, Cairns DA, at al. Initial development and validation of a novel extraction method for quantitative mining of the formalin-fixed, paraffinembedded tissue proteome for biomarker investigations. J Proteome Res 2010;10:896-906.
19. Krishhan W, Khan IH, Luciw PA. Multiplexed microbead immunoassays by flow cytometry for molecular profiling: basic concepts and proteomics applications. Crit Rev Biotechnol 2009;29:29-43.
20. Cha S, Imielinski MB, Rejtar T, Richardson EA, Thakur D, Sgroi DC, at al. In situ proteomic analysis of human breast cancer epithelial cells using laser capture microdissection: annotation by protein set enrichment analysis and gene ontology. Mol Cell Proteomics 2010;9:2529-44.
21. Anderson KS, Sibani S, Wallstrom G, Qiu J, Mendoza EA, Raphael J, at al. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res 2011;10:85-96.
22. Bateman NW, Sun M, Hood BL, Flint MS, Conrads TP. Denning central themes in breast cancer biology by differential proteomics: conserved regulation of cell spreading and focal adhesion kinase. J Proteome Res 2010;9:5311-24.
23. 18O-labeling to identify biomarkers for cholangiocarcinoma. J Proteome Res 2008;7:4670-7.
24. An HJ and Lebrilla CB. A glycomics approach to the discovery of potential cancer biomarkers. Methods Mol Biol 2010;600:199-213.
25. Choudhary C and Mann M. Decoding signalling networks by mass spectrometry-based proteomics. Nat Rev Mol Cell Biol 2010;11:427-39.
26. Madian AG and Régnier FE. Profiling carbonylated proteins in human plasma. J Proteome Res 2010;9:1330-43.
27. Iwabata H, Yoshida M, Komatsu Y. Proteomic analysis of organspecific post-translational lysine-acetylation and -methylation in mice by use of anti-acetyllysine and -methyllysine mouse monoclonal antibodies. Proteomics 2005;5:4653-64. (Pubitemid 43016886)
28. Ceroni A, Sibani S, Baiker A, Pothineni VR, Bailer SM, LaBaer J, et al. Systematic analysis of the IgG antibody immune response against varicella zoster virus (VZV) using a self-assembled protein microarray. Mol Biosyst 2010;6:1604-10.
29. Wong J, Sibani S, Lokko NN, LaBaer J, Anderson KS. Rapid detection of antibodies in sera using multiplexed self-assembling bead arrays. J Immunol Methods 2009;350:171-82.
30. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010;56:177-85.
31. Osterfeld SJ, Yu H, Gaster RS, Caramuta S, Xu L, Han SJ, et al. Multiplex protein assays based on real-time magnetic nanotag sensing. Proc Natl Acad Sci USA 2008;105:20637-40.
32. Paulovich AG, Billheimer D, Ham AJ, Vega-Montoto L, Rudnick PA, Tabb DL, et al. Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance. Mol Cell Proteomics 2010;9:242-54.
33. Rudnick PA, Clauser KR, Kilpatrick LE, Tchekhovskoi DV, Neta P, Blonder N, et al. Performance metrics for liquid chromatographytandem mass spectrometry systems in proteomics analyses. Mol Cell Proteomics 2010;9:225-41.
34. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, at al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009;27:633-41.
35. Tabb DL, Vega-Montoto L, Rudnick PA, Variyath AM, Ham AJ, Bunk DM, et al. Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J Proteome Res 2010;9:761-76.
36. Rodriguez H, Snyder M, Uhlén M, Andrews P, Beavis R, Borchers C, et al. Recommendations from the 2008 international summit on proteomics data release and sharing policy: the amsterdam principles. J Proteome Res 2009;8:3689-92.
37. Gloriam DE, Orchard S, Bertinetti D, Björling E, Bongcam-Rudloff E, Borrebaeck CA, et ai A community standard format for the representation of protein affinity reagents. Mol Cell Proteomics 2010;9:1-10.
38. Xu X, Zhang J, Zhang L, Liu W, Weisel CP. Selective detection of monohydroxy metabolites of polycyclic aromatic hydrocarbons in urine using liquid chromatography/triple quadrupole tandem mass spectrometry. Rapid Commun Mass Spectrom 2004;18:2299-308. (Pubitemid 39297367)
39. Xu X, Roman JM, Issaq HJ, Keefer LK, Veenstra TD, Ziegler RG. Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandem mass spectrometry. Anal Chem 2007;79:7813-21.
40. James A and Jorgensen C. Basic design of MRM assays for peptide quantification. Methods Mol Biol 2010;658:167-85.
41. Kiyonami R, Schoen A, Prakash A, Peterman S, Zabrouskov V, Picotti P, et al. Increased selectivity, analytical precision, and throughput in targeted proteomics. Mol Cell Proteomics 2011;10: M110.002931.
42. Gerszten RE, Carr SA, Sabatine M. Integration of proteomic-based tools for improved biomarkers of myocardial injury. Clin Chem 2010;56:194-201.
43. Kuhn E, Wu J, Karl J, Liao H, Zolg W, Guild B. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and "C-labeled peptide standards. Proteomics 2004;4:1175-86.
44. Kuhn E, Addona T, Keshishian H, Burgess M, Mani DR, Lee RT, et al. Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem 2009;55:1108-17.
45. Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J Proteome Res 2004;3:235-44.
46. Ahn YH, Lee JY, Lee JY, Kim YS, Ko JH, Yoo JS. Quantitative analysis of an aberrant glycoform of TIMPl from colon cancer serum by L-PHA-enrichment and SISCAPA with MRM mass spectrometry. J Proteome Res 2009;8:4216-24.
47. Reid JD, Holmes DT, Mason DR, Shah B, Borchers CH. Towards the development of an immuno MALDI (iMALDI) mass spectrometry assay for the diagnosis of hypertension. J Am Soc Mass Spectrom 2010;21:1680-6.
48. Jiang J, Parker CE, Fuller JR, Kawula TH, Borchers CH. An immunoaffinity tandem mass spectrometry (iMALDI) assay for detection of Francisella tularensis. Anal Chim Acta 2007;605:70-9. (Pubitemid 350088652)
49. Mansfield E, O'Leary TJ, Gutman SI. Food and drug administration regulation of in vitro diagnostic devices. J Mol Diagn 2005; 7:2-7. (Pubitemid 40310159)
50. U.S. Food and Drug Administration (FDA). FDA/CDRH Public Meeting: oversight of Laboratory Developed Tests (LDTs), July 19-20, 2010. http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm212830.htm (Updated on Sep 2010).
51. Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 2010;28:827-38.
52. Center for Devices and Radiological Health (CDRH). Draft guidance for industry, clinical laboratories, and FDA staff in vitro diagnostic multivariate index assays, http://www.fda.gov/downloads/ MedicalDevices/ DeviceRegulationandGuidance/GuidanceDocuments/ucm071455.pdf (Updated on Jul 2007).
53. U.S. Food and drug administration. 510(k) Substantial equivalence determination decision summary. http://www.accessdata. fda.gov/cdrh-docs/ reviews/K081754.pdf (Updated on Mar 2011).
54. Rodriguez H, Tezak Z, Mesri M, Carr SA, Liebler DC, Fisher SJ, at al. Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics. Clin Chem 2010;56:237-43.
55. Regnier FE, Skates SJ, Mesri M, Rodriguez H, Tezak Z, Kondratovich MV, et al. Protein-based multiplex assays: mock presubmissions to the US food and drug administration. Clin Chem 2010;56: 165-71.
56. Pacini F. Follow-up of differentiated thyroid cancer. Eur J Nud Med Mol Imaging 2002;29(S2):S492-6. (Pubitemid 34985350)
57. Saghari M, Gholamrezanezhad A, Mirpour S, Eftekhari M1 Takavar A, Fard-Esfahani A, et al. Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan. Nucl Med Commun 2006;27:567-72. (Pubitemid 44305312)
58. Spencer CA. Recoveries cannot be used to authenticate thyroglobulin (Tg) measurements when sera contain Tg autoantibodies. Clin Chem 1996;42:661-3.
59. Spencer CA. Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab 2004; 89:3702-4. (Pubitemid 39071459)
60. Preissner CM, O'Kane DJ, Singh RJ, Morris JC, Grebe SK. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab 2003;88:3069-74. (Pubitemid 36877474)
61. Hoofnagle AN, Becker JO, Wener MH, Heinecke JW Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem 2008;54:1796-804.
62. Hoofnagle AN. Peptide lost and found: internal standards and the mass spectrometric quantification of peptides. Clin Chem 2010; 56:1515-7.
63. Ciccimaro E, Hanks SK, Yu KH, Blair IA. Absolute quantification of phosphorylation on the kinase activation loop of cellular focal adhesion kinase by stable isotope dilution liquid chromatography/ mass spectrometry. Anal Chem 2009;81:3304-13.
64. U.S. Food and Drug Administration (FDA). CFR-Code federal regulations title 21. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch. cfin?fr=862.2860 (Updated on Apr 2010).
65. Clinical and Laboratory Standards Institute (CLSI). http://www. clsi.org (Updated on Feb 2011).
66. Spitz MR and Bondy ML. The evolving discipline of molecular epidemiology of cancer. Carcinogenesis 2010;31:127-34.
67. Rosa DD, Ismael G, Lago LD, Awada A. Molecular-targeted therapies: lessons from years of clinical development Cancer Treat Rev 2008;34:61-80.
68. Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, Renfrew JJ, at al. A network model of a cooperative genetic landscape in brain tumors. JAMA 2009;302:261-75.
69. International Cancer Genome Consortium. International network of cancer genome projects. Nature 2010;464:993-8.
70. Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
71. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, at al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NFl. Cancer Cell 2010;17:98-110.